Literature DB >> 24324224

Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.

Claudia Slimings1, Thomas V Riley.   

Abstract

OBJECTIVES: To update the evidence for associations between antibiotic classes and hospital-acquired Clostridium difficile infection (HA-CDI).
METHODS: Electronic databases of journal articles, scholarly theses and conference proceedings using subject headings and keywords related to CDI and antibiotic exposure were searched. Observational epidemiological studies measuring associations between antibiotic classes and HA-CDI were eligible for inclusion. Pooled ORs and 95% CIs were calculated using a random effects model. Study factors identified a priori were examined as sources of heterogeneity. The quality of the studies was assessed using the Newcastle-Ottawa Scale.
RESULTS: Of 569 citations identified, 13 case-control and 1 cohort study (15,938 patients) were included. The strongest associations were found for third-generation cephalosporins (OR = 3.20, 95% CI = 1.80-5.71; n = 6 studies; I(2) = 79.2%), clindamycin (2.86, 2.04-4.02; n = 6; I(2) = 28.5%), second-generation cephalosporins (2.23, 1.47-3.37; n = 6; I(2)  = 48.4%), fourth-generation cephalosporins (2.14, 1.30-3.52; n = 2; I(2)  = 0.0%), carbapenems (1.84, 1.26-2.68; n = 6; I(2) = 0.0%), trimethoprim/sulphonamides (1.78, 1.04-3.05; n = 5; I(2) = 70%), fluoroquinolones (1.66, 1.17-2.35; n = 10; I(2) = 64%) and penicillin combinations (1.45, 1.05-2.02; n = 6; I(2) = 54%). The study population and the timing of measurement of antibiotic exposure were the most common sources of heterogeneity. Study quality scored high for seven studies, moderate for six studies and low for one study.
CONCLUSIONS: The risk of HA-CDI remains greatest for cephalosporins and clindamycin, and their importance as inciting agents should not be minimized. The importance of fluoroquinolones should not be overemphasized, particularly if fluoroquinolone-resistant epidemic strains of C. difficile are absent.

Entities:  

Keywords:  antimicrobials; diarrhoea; healthcare facilities; risk factors

Mesh:

Substances:

Year:  2013        PMID: 24324224     DOI: 10.1093/jac/dkt477

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  152 in total

Review 1.  Dentists, antibiotics and Clostridium difficile-associated disease.

Authors:  N Beacher; M P Sweeney; J Bagg
Journal:  Br Dent J       Date:  2015-09-25       Impact factor: 1.626

2.  Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.

Authors:  Mark D Gonzalez; Meghan A Wallace; Tiffany Hink; Erik R Dubberke; Carey-Ann D Burnham
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

Review 3.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 4.  MRSA: treating people with infection.

Authors:  Nikolas Rae; Anna Jarchow-MacDonald; Dilip Nathwani; Charis Ann Marwick
Journal:  BMJ Clin Evid       Date:  2016-02-16

5.  Clinical outcomes and costs associated with procalcitonin utilization in hospitalized patients with pneumonia, heart failure, viral respiratory infection, or chronic obstructive pulmonary disease.

Authors:  Stacy Aric Johnson; Austin Bernard Rupp; Kirsten Leigh Rupp; Santosh Reddy
Journal:  Intern Emerg Med       Date:  2021-01-16       Impact factor: 3.397

Review 6.  Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.

Authors:  Alyse L Frisbee; William A Petri
Journal:  Trends Mol Med       Date:  2020-02-17       Impact factor: 11.951

Review 7.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

Review 8.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

9.  Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.

Authors:  Kevin Antoine Brown; Bradley Langford; Kevin L Schwartz; Christina Diong; Gary Garber; Nick Daneman
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

10.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.